This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Catherine Angell Sohn is an American businesswoman, pharmacist, and consultant specializing in therapeutic commercialization and licensing.
Catherine Angell Sohn, Pharm.D. | |
|---|---|
| Alma mater | University of California, San Francisco; University of Pennsylvania Wharton School |
| Scientific career | |
| Institutions | GlaxoSmithKline |
Education edit
Sohn studied biochemistry at the University of California, Davis and later studied clinical pharmacy at the University of California, San Francisco, receiving her Pharm.D. in 1977. She completed a Professional Development certificate at the Wharton School in 2006.
Career edit
Sohn spent nearly 30 years working in various roles within GlaxoSmithKline, from 1982 to her retirement in 2010. Her career included stints in medical affairs, strategic product development, product marketing, development of the U.S. Vaccines division, launch of the CNS-active therapeutic Paxil, mergers and acquisitions, and finally a Senior Vice President in the Consumer Health division.[1]
Dr. Sohn serves on the Boards of Directors for Jazz Pharmaceuticals, Rubius Therapeutics, Axcella Health and Landec Corporation.[2] She is an Adjunct Professor in Clinical Pharmacy at UCSF.[3]
Awards edit
References edit
- ^ Sohn, Catherine (2011). "EDGE Conference Speaker Bio" (PDF). HBA Edge Conference. Retrieved 26 October 2018.
- ^ "Neuralstem Appoints Catherine Angell Sohn To Board Of Directors :: Neuralstem, Inc. (CUR)". Neuralstem, Inc. 14 January 2014. Retrieved 2018-10-26.
- ^ a b "Catherine Sohn | UCSF Profiles". profiles.ucsf.edu. Retrieved 2018-10-26.
- ^ "Frank Barnes Award - Licensing Executives Society (LES)". www.lesusacanada.org. Retrieved 2018-10-26.
- ^ Letter, The Pharma. "GSK's Catherine Sohn named US Healthcare Businesswomen's Association". www.thepharmaletter.com. Retrieved 2018-10-26.